While these might seem like minor technical changes, they have significant implications for supplement testing
While the specific length of treatment depends on your plan with your doctor, it appears that GLP-1s should be used longterm to maintain weight loss
By extrapolation from the established profiles of approved GLP-1 receptor agonists including semaglutide (Wegovy SmPC, MHRA/EMC) and tirzepatide (Mounjaro SmPC, MHRA/EMC) clinicians should anticipate the need to review and potentially reduce antihypertensive doses as significant weight loss occurs, in line with BNF and NICE guidance principles
For Reference A new study (PubMed ID: 38218536) looked at combining GLP-1 receptor agonists with ActRII inhibitors, a class of therapies that can block pathways linked to muscle breakdown
Because in my opinion what happens in the oral space, will determine the next winner
ERR agonism the primary driver ERR is highly expressed in energy-demanding tissues such as skeletal muscle, heart, brown adipose tissue, and liver